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Desmoplastic Small Round Cell Tumor (DSRCT) has a very poor prognosis. This report illustrates novel chemotherapy and local
control interventions in a 5-year old patient. The patient was treated in the outpatient setting, achieved remission, with excellent
quality of life. The patient presented with massive ascites and >1000 abdominal tumors. Neoadjuvant chemotherapy included
vincristine (1.5mg/m2), ifosfamide (3g/m2/day × 3), dexrazoxane/doxorubicin (750/75mg/m2), and etoposide (150mg/m2).
Continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin (100mg/m2) was given after extensive cytoreductive
surgery. This was followed by irinotecan (10mg/m2/day × 5 × 2 weeks) + temozolomide monthly × 2, then abdominal radiation
30Gy with simultaneous temozolomide (100mg/m2/day × 5). A total of 12 cycles of irinotecan and temozolamide were given.
Except for initial chemotherapy, subsequent courses were in the outpatient setting. Focal retroperitoneal relapse at 18 months
was treated with IMRT with bevacizumab (5mg/kg) and 2 perihepatic metastases with radio frequency ablation/cryoablation
followed by chronic outpatient maintenance chemotherapy (valproic acid, cyclophosphamide, and rapamycin). Almost 2 years
from diagnosis, the patient maintained an excellent quality of life. This is a novel approach to the treatment of children with
massive abdomino-pelvic DSRCT.
Copyright © 2008 Dolly Aguilera et al. Thisis an open access articledistributedunder theCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
DSRCT is an aggressive neoplasm usually involving numer-
ous peritoneal metastases. It can also occur in diﬀerent lo-
cations including the intrathoracic cavity, pleura, parat-
esticular, and soft tissues. A speciﬁc recurring t(11;22)
translocationinvolvingEWSandWT-1isacharacteristic[1].
Since the initial description of DSRCT by Gerald and Rosai
[2] in 1991, signiﬁcant progress has been made in its patho-
logic identiﬁcation and diagnosis. However, despite multiple
treatment strategies among them, several chemotherapy
regimens active for Ewing’s sarcoma, aggressive debulking
surgery, whole abdominal radiation, high-dose chemother-
apy with autologous stem cell transplant, DSRCT survival
has not signiﬁcantly improved. Despite much time in the
hospital and morbidity of interventions, durable remissions
remain rare. Preliminary data supports the combination of
standard treatment modalities with continuous hyperther-
mic peritoneal perfusion (CHPP) in adult patients with
peritoneal carcinomatosis [3–6]. Thus, CHPP may be a
rational approach to improve local control of patients with
DSRCT [7]. Experience with active chemotherapy agents
for DSRCT in the outpatient clinic and also home infusion
settings are presented here.
2. CASE HISTORY
A 5-year old patient presented to an outside institution with
one-week history of abdominal pain and severe constipa-
tion not improved with laxatives. Worsening of symptoms
and abdominal distention prompted additional evaluation.
Abdominal CT scan demonstrated extensive peritoneal mas-
ses (6cm right lower abdomen; 5cm between rectum and
bladder, 8cm pelvic ﬂoor above the bladder), peritoneal and2 Sarcoma
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Figure 1: Peritoneal nodule of DSRCT at diagnosis. Nodules are composed of ﬁbrocollagenous tissue and irregular islands of malignant
undiﬀerentiatedsmallroundcells.Immunoperoxidasestains(notshown)inthiscasewerestronglypositiveforEMA,vimentin,anddesmin,
partially positive for CD99 and negative for synaptophysin, chromogranin, myogenin, SMA, Bcl-2, CD3, and CD20. Cytogenetic analysis
demonstrated t(11;22)(p15;q12). Magniﬁcation: (a) × 10, (b) × 40, (c) high power.
omental implants (estimated number of metastases >1000),
and massive ascites. There were many perihepatic lesions,
but no obvious tumors within the liver. The patient was
referred to MD Anderson Cancer Center, Children’s Cancer
Hospital. An exploratory laparotomy was done for biopsy
and staging purposes; ascites was drained and a temporary
peritoneal catheter for ascites removal was placed. The tu-
mor was limited to the abdominal cavity. Other organs
had no evidence of disease. Histologic exam of the ascities
ﬂuid demonstrated some DSRCT cells in a background of
lymphocytosis.
Pathology of tumor biopsies (see Figure 1) showed fea-
turesofahighlyanaplasticandsomewhatpleomorphicsmall
blue cell malignancy. The immunohistochemical proﬁle
included: EMA 4+ in 75% of neoplastic cells with cytoplas-
mic (granular) pattern; Vimentin: 4+ in 95% of neoplastic
cells with cytoplasmic ﬁnely and coarsely granular pattern,
CD-99/Myc-2 2+ immunoreactivity in 30% of neoplastic
cells cytoplasmic and granular pattern, Desmin 4+ in 95%
of tumor cells, Myogenin (-), SMA (-), Bcl-2 (-), CD3 (-),
CD20(-),Synaptophysin(-),Chromogranin(-).Cytogenetic
analysis conﬁrmed the presence of t(11;22)(p15;q12)by
FISH characteristic of DSRCT.
2.1. Preadjuvantchemotherapytreatment
Figure 2 shows a sequence of Neoadjuvant and adjuvant
chemotherapy. First cycle was vincristine (1.5mg/m2), cy-
clophosphamide (2.2g/m2), and doxorubicin (75mg/m2)a s
an inpatient. Subsequent chemotherapy was outpatient and
used a modiﬁed “VIDE” regimen similar to EuroEwings
protocolseverythreeweeksin4cycles.Vincristine1.5mg/m2
was followed by dexrazoxane (750mg/m2 IV over 15 min-
utes) + doxorubicin (75mg/m2 IV over 15 minutes) and
etoposide (150mg/m2 IV over 1 hour). Ifosfamide (3g/m2)
was mixed with MESNA (3g/m2/day) in volume of 240mL
normal saline and given as a continuous infusion × 3d a y s
(total dose 9g/m2) followed by 1 day of MESNA (3g/m2).
Pegﬁlgrastim was given after completion of MESNA when
port was deaccessed by the home health nurse.
Day 1 chemotherapy was given in the outpatient clinic;
ifosfamide infusions were done at home with bag changes by
home health nursing. The patient had excellent performance
and attended elementary school. Just prior to local control
surgery, an additional cycle consisting of vincristine and
liposomal doxorubicin (40mg/m2 IV over 3 hours with
hands and feet on ice to reduce risk of palmar/plantar ery-
throdysesthesia) was administered. Total anthracycline dose
was 415mg/m2.
2.2. Localcontrolphaseoftherapy:
CHPPandradiation
Five months from initial presentation, and after approval
by the institutional review board, the patient underwent
aggressive cytoreductive surgery including greater and lesser
omentectomy, cholecystectomy and partial peritonectomy
and removal of 402 metastatic nodules.
At the end of the surgical procedure, cisplatin 100mg/m2
at 40–42◦C was continuously perfused in the peritoneal
cavity. CHPP (Figure 3) consisted of the placement of 7
temperature probes: (1) ligament of Treitz, (2) right lobe of
the liver, (3) right upper quadrant, (4) left upper quadrant,
(5) right lower quadrant, (6) left lower quadrant, and (7)
sigmoid colon mesentery. The abdomen was then closed
temporarily to secure the inﬂow and outﬂow cannulas. A
Y-shaped inﬂow cannula was placed above the liver, and a
pelvic drain was placed in the pelvis.
Plasmalyte was perfused for 15 to 20 minutes to establish
equivalent temperatures. When average temperatures of
40◦C were established in all portions of the abdomen, cis-
platin 100mg/m2 was added to the perfusate simultaneousDolly Aguilera et al. 3
Vincristine, doxorubicin, ifosfamide, etoposide (VIDE)
4m o n t h s
Surgery + CHPP (cisplatin)
Temozolomide + irinotecan
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Abdominal radiation (30Gy) liver radiation (15Gy)
+T e m o z o l o m i d e×2 weeks
Temozolomide + irinotecan (home chemotherapy)
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Follow-up
Figure 2: Outpatient neoadjuvant and adjuvant chemotherapy plan
for DSRCT. After initial diagnosis and treatment of peritoneal,
abdominal and pelvic disease, systemic chemotherapy agents were
administered on an outpatient basis followed by local control with
cytoreductive surgery + CHPP with cisplatin, then whole abdomen
radiation with temozolomide as a radiation sensitizer, followed by
temozolomide and irinotecan. Outpatient therapy was 15 months.
with the beginning of an intravenous infusion of sodium
disulfate. The abdomen was continuously agitated for 90
minutes, temperatures were monitored frequently, and agi-
tation was adjusted according to the temperature of each
probe. The temperature of the inﬂow and the thermomistor
was 45◦C. Temperature in the intra-abdominal probes was
about 41-42◦C. The volume was 2.5 liters. Flow rate was
700mL/minute throughout the 1.5 hour CHPP procedure.
Cisplatin was drained, and then two liters of Plasmalyte at
room temperature were infused to rinse cisplatin from the
peritoneal cavity. Abdomen was reopened and inspected.
Gastrostomy and jejunostomy tubes were placed in antici-
pation of enteral nutrition in the post-operatory period. The
patient had a rapid recovery and was discharged from the
hospital to home 7 days after surgery.
Pathology evaluation from peritoneal tumor nodules
reported minimal residual malignant small tumor cells in
most of the specimens consistent with microscopic residual
disease.
2.3. AdjuvantDSRCTchemotherapyand
radiosensitizationprogram
Outpatient and home chemotherapy were provided before
and during radiation (6 months from diagnosis) and then
for an additional 8 cycles until 14 months after diagnosis.
Regimen was similar to that reported by Wagner et al. [8].
Temozolamide (100mg/m2/day × 5 days) and irinotecan
(10mg/m2/day × 5d a y s× 2 weeks) for 2 four-week cycles.
During total abdominal radiation (3Gy × 10 fractions; total
30Gy and 15Gy to the liver/kidneys) irinotecan was not
given and only temozolomide (100mg/m2/dose × 5d a y s×
2 cycles) was provided. After radiation, 8 cycles of temo-
zolomide + irinotecan were given. Day 1: temozolomide and
irinotecan were given in the outpatient clinic each month.
Days 2–5 and 8–12: irinotecan chemotherapy infusions were
done at home (after school) using home health nursing.
The patient tolerated this chemotherapy well and had
one, brief hospitalization for fever and neutropenia. He
was able to attend elementary school with almost perfect
attendance.
2.4. Relapse:additionallocalcontrolwithIMRT,
thenradiofrequencyablation+cryoablation
Although the patient continued to be healthy, attend school,
and had no symptoms, routine PET-CT done 2 months
after completion of therapy showed ﬁve FDG avid areas
(Figure 4). All were just outside of the peritoneum and at
edge or outside prior radiation ﬁelds: two adjacent posterior
perihepatic, one at the dome of the right diaphragm, and
2 retroperitoneal pericaval nodes. IMRT (1.5Gy in 15 frac-
tions; total 45Gy) was given to the retroperitoneal disease.
Radiosensitization was with temozolomide (75mg/m2/day
× 5d a y s× 2 weeks), bevacizumab (5mg/kg every 2 weeks
× 3 doses), valproate (500mg/m2/day divided BID), and
rapamycin (2mg/m2/day). The patient tolerated radiother-
apy well and had no side eﬀects.
Hewasreimagedandtheadjacentperihepaticlesionshad
increased in size from 3.0 × 1.5cm to approximately 3.8 ×
2.6cm and from 3.3 × 1.3cm to 4.3 × 2.2cm; there was no
changeinsizeofthe1cmdomeofrightdiaphragmlesion.To
destroy cells in the perihepatic nodules and increase chance
of mounting an immune response, both radio frequency
ablation and cryoablation were used (Figure 5). Under direct
CT ﬂuoroscopic guidance, a radio frequency ablation (RFA)
electrode (RITA system) was used to heat the tumor to 42-
43◦C for 30 minutes, then each lesion was frozen using
a cryoablation probe (PERC-17; Endocare) for 2 cycles of
freezing (5–10 minutes) and thawing (5–8 minutes). The
patient tolerated the procedure well and was observed in the
hospitalovernight.Hehadnosideeﬀectsfromtheprocedure
except for some skin reaction and scab which resolved in 2
weeks.
2.5. Chronicadjuvantchemotherapy
programandfollowup
The patient received a regimen of valproate (250mg BID),
rapamycin (2mg daily), and sorafenib (200mg BID) and
chemotherapy similar to that reported by Casanova et al.
[9], vinorelbine (25mg/m2 IV monthly) and oral cyclophos-
phamide (25mg daily) (see Figure 6). Sorafenib and vinor-
elbine were discontinued because of signiﬁcant diarrhea4 Sarcoma
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Figure 3: Continuous hyperthermic peritoneal perfusion (CHPP). The CHPP procedure involves placing temperature probes, inﬂow and
outﬂow cannulas, and continuous perfusion of plasmalyte followed by cisplatin containing chemotherapy as the perfusate at 41-42◦C. To
achieve this, the inﬂow was usually about 45◦C. Manual agitation of the closed abdomen was done for 1.5 hours to ensure that all peritoneal
surfaces were exposed to the cisplatin.
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Figure 4: PET-CT fusion imaging. (a) Residual uptake in the peritoneal implants after 2 cycles of therapy, SUV 3. (b) No evidence of FDG
avid disease after cytoreductive therapy. (c) Relapse in the perihepatic space including dome of the liver (SUV 2.8) and retroperitoneal nodes
(SUV 5).Dolly Aguilera et al. 5
P
R
1
(a) (b) (c)
Figure 5: Radio frequency ablation and cryoablation procedure. Under direct CT ﬂuoroscopic guidance, an RFA electrode was advanced into
the perihepatic lesions. These were heated from 42◦Ct o4 3 ◦C for 30 minutes (a) and (b) then a cryoablation probe was advanced and 2
cycles of freeze and thaw for 8–10 minutes (c).
(see treatment schema in Figure 6). The patient attended
school full time without symptoms.
For almost 2 years from diagnosis of massive disease at
DSRCT, this patient has had only 32 days of hospitalization
including initial admission of 18 days, 3 days for hydration,
1 episode for hematuria, 2 days for fever and neutropenia,
7 days for CHPP surgery, and 1 overnight observation for
RFA + cryoablation. He will continue on a maintenance
chemotherapy regimen and be followed with PET-CT fusion
imaging every 3 months.
3. RESULTS
3.1. Effectivechemotherapyasanoutpatient
Once ascites improved after initial chemotherapy cycle,
subsequent cycles were given in the outpatient clinic. For 13
out of 14 cycles, only day 1 was given at the major medical
center, days 2–4 ifosfamide or 2–12 irinotecan were given at
home using home infusion services.
Responsetoinitialchemotherapy(Table 1)wasevaluated
with abdominal CT scans interpreted as a very good partial
response (Figure 4), more than 50% reduction of the peri-
hepatic, pelvic, and omental implants when compared with
initial CT imaging studies. After one cycle of chemotherapy,
PET scan demonstrated diﬀuse nodules and less ascites
throughout the abdomen. PET-CT demonstrated low-grade
FDG activity (maximal SUV 3). After completion of 4
months of VIDE, PET scan continued to demonstrate low-
FDG uptake in the perihepatic implant with maximum SUV
measured at 3 (stable disease). Other nodules did not show
signiﬁcant uptake probably because of small size (<1cm).
PET scan after cytoreductive surgery, CHPP, and one cycle of
temozolamide /irinotecan showed residual activity over the
dome of the right lobe of the liver may be post treatment-
related or post-surgical in nature. After completion of
abdominal radiation and temozolomide with irinotecan (6
cycles), there was no evidence of FDG avid disease. This was
considered a clinical complete remission.
3.2. Excellentqualityoflifeduringoutpatient
andhomechemotherapyprogram
Except for the initial chemotherapy, the treatment regimen
for this patient was in the outpatient or home setting, allow-
ing him to have excellent quality of life. This allowed school
attendance and play at home. Generally home ifosfamide
bag changes or irinotecan infusions could be done after
school.
3.3. Approachtohigh-riskstatus:surveillance
detectsrecurrencebeforesymptoms
Because the patient had a high risk of recurrence, based
on the initial presentation with massive ascities and very
large number of peritoneal implants, close monitoring for
relapse was necessary with PET-CT imaging fusion every 12
weeks during and after therapy. This resulted in detection
of recurrence before appearance of clinical symptoms. The
PET-CT also provided information useful in IMRT treat-
ment planning.
Chronic adjuvant chemotherapy: well tolerated.
The current therapy designed to treat an Ewing’s family
of tumor using agents compatible with outpatient or home
therapy that could be given for months to years. Because
of high-risk status, a long term therapy is planned. The
toxicity has been with minimal with two episodes of fever
and neutropenia or illness associated with chemotherapy
administration to date.
4. DISCUSSION
In this report, we have shown a child with high-risk DSRCT
with massive disseminated peritoneal DSRCT implants
who had complete response and sustained a remission for6 Sarcoma
Table 1: Outpatient DSRCT chemotherapy: doses and schedule.
Agent Dose Route Comments
Preadjuvant phase of therapy (every 3 weeks × 4c y c l e s )
Vincristine 1.5mg/m2 iv over 2–15 minutes Max dose 2 mg; day 1 only
Etoposide 150mg/m2 i vo v e r1h o u r D a y1o n l y
Dexrazoxane 750mg/m2 iv over 15 minutes Just before doxorubicin
Doxorubicin 75mg/m2 iv over 15 minutes Day 1 only
Ifosfamide 3g/m2 iv daily × 3 Continuous infusion. Mix
+M E S N A 3g / m 2 iv daily × 4 with MESNA in 240–360 mL NS days 1, 2, 3.
MESNA only day 4 (portable pump as outpatient)
CHPP phase
Cisplatin 100mg/m2 Intraperitoneal As continuous peritoneal perfusion at 42◦C × 1.5 hr
Radio sensitization during RT
Temozolomide 75mg/m2 po Daily × 5 × 2w e e k s
Bevacizumab 5mg/kg iv q2 weeks × 2d o s e sb e g i nb e f o r eR T
Pre-RT (2 cycles) and post-RT (10 cycles)
Temozolomide 100mg/m2 po Daily × 5e a c hm o n t h
Irinotecan 10mg/m2 iv Daily × 5 × 2 weeks each month; may do as home
infusions
Chronic continuation chemotherapy
Valproate 500mg/m2 po Daily; divide BID monitor level <100
Rapamycin 2mg/m2 po Daily round to nearest mg
Cyclophosphamide 25mg po If >1.5m2 may give 50mg daily. Monitor cbc
21 months following therapy with a carefully designed mul-
timodality outpatient and home treatment plan.
DRSCT has a 15% overall survival at 5 years [10].
Patientspresentingwithabdominaldiseasetypicallyareinan
advancedstage,withlargemassesand/orextensiveseedingin
the visceral and parietal peritoneal layers. Thus, DSRCT in
the abdomen is almost always disseminated regionally. The
presence of the translocation t(11:22) (p13:q12) involving
fusion of the Ewing sarcoma gene (EWS) and the Wilm’s
tumor gene (WT1) provides the conﬁrmation of diagnosis
[1, 11].
Chemotherapy agents with known activity in DSRCT are
very similar to those active in Ewing Sarcoma. Both tumors
share an EWS fusion protein and may also share molecular
mechanisms facilitating proliferation and survival pathways.
Alkalyting agents such as cyclophosphamide and ifosfamide
are important components of therapy. Currently, a well-
recognized treatment schema has been reported by Kushner
et al. [12] who described results in 12 DSRCT patients. This
intensive alkylator-based therapy used cyclophosphamide,
doxorubicin, vincristine alternating with ifosfamide and
etoposide. Its combination with other treatment modalities
such as surgery, radiation, autologous stem cell rescue, or
the combination of all of the above was used. The median
survival time was 19 months. For those achieving complete
response, the median followup in this series was 22 months,
about the same as our patient. The toxicity for this regimen
canbesubstantialandoftenincludeshospitalizationnotonly
for chemotherapy, but also fevers associated with myelosu-
pression and mucositis. Our outpatient and home program
had signiﬁcantly less hospitalization and very tolerable side
eﬀects. It permitted routine school attendance; play activities
were possible with an excellent quality of life.
In our patient, ifosfamide/mesna as a continuous infu-
sion as previously described by Skubitz et al. [13], was well
tolerated and allowed treatment in the outpatient setting.
No hydration is required. Since a small volume (e.g., 240–
360mL/day) can be infused, this permits a normal pattern
of sleep. Irinotecan activity in sarcoma has been shown by
Bisogno et al. [14]a n dW a g n e re ta l .[ 8]. We also have
observed high activity of the temozolomide + irinotecan
combination in relapsed Ewing’s sarcoma and 2 previous
patients with DSRCT [15]. Rossof and Bayliﬀ described
successful responses in DSRCT cases to irinotecan [16].
The toxicity of temozolomide and irinotecan was very low.
Our patient did not experienced documented infections;
home infusions of irinotecan were routine and done after
school.
Epigenetic alterations of DSRCT are probable since EWS
is associated with responses to such agents. For example, the
eﬀects of histone deacetylase (HDAC) inhibitors in Ewing’s
family tumors was recently described by Sakimura et al.
[17]. This group showed expression of the EWS-Fli1 fusion
RNA and fusion protein was inhibited with desipeptide.
Recent preliminary work shows that both HDAC and mTOR
inhibitors are promising not only for EWS, but also DSRCT
[18–20]. Low dose of cyclophosphamide has activity in
pediatric sarcoma [9]. We have used this information in
the design of a chronic, well-tolerated outpatient adjuvant
therapy in our DSRCT patient.Dolly Aguilera et al. 7
Retroperitoneal IMRT (45Gy)
Bevacizumab q2 weeks ×3
Temozolamide ×5d a y s×2 weeks
Valproate BID
Rapamycin daily
RFA probe (42◦C) for liver lesions
30min
Cryoablation (freeze- thaw) ×2c y c l e s
10min
Chronic maintenance regimen ×3c y c l e s
PET-CT scan q3 months
Vinorelbine Q month
Cyclophosphamide daily
Sorafenib BID
Valproate BID
Rapamycin daily
Figure 6: Schema for local control of relapse foci and continuation
adjuvant therapy. Radiation in combination with bevacizumab was
used to pericaval disease. Localized perihepatic lesions were treated
with a combination of RFA and cryoablation. These measures were
followed with a chronic adjuvant regimen.
Immuno-histochemistry studies revealed in several in-
tra-abdominal DSRCT specimens, upregulation in tumor
cells of platelet derived growth factor AB chain and platelet
derived growth factor alpha receptor [21]. Perhaps these
ﬁndings support additional contributions towards tumor
survival and/or apoptosis resistance. Thus sorafenib, a mul-
tikinase inhibitor that directly inhibits the autophosphory-
lation of several receptor tyrosine kinases including PDGFR
beta, and c-kit may have additional activity beyond VEGF
receptor inhibition [22].
Local control is important in DSRCT [10]. In our patient
local control measures included surgery with CHPP [5–7,
23], abdominal radiation with radiosensitizing chemother-
apy during the ﬁrst cycle (temozolamide) and with beva-
cizumab during radiation for relapse [24]. The initial role of
surgery in patients with extensive intra-abdominal disease is
often limited to biopsies; after chemotherapy response this is
followed by a debulking procedure. Saab et al. [25]r e p o r t e d
a series of patients with abdominopelvic DRSCT with
incomplete resection, in which total surgical resection was
not feasible; outcome was poor.
Aggressive cytoreductive surgery is currently accepted to
have a primary role in the achievement of prolonged survival
of some malignancies involving the peritoneum [4, 6]. In
DSRCT Lal reported 3-year OS was 58% in gross total
resection in comparison with 0% in the nonresection cohort
[10]. Other therapeutic modalities such as CHPP have been
found to signiﬁcantly improve outcome in cancer involving
the peritoneum [6, 23, 26–28]. Although Gil et al. [29]
showed no beneﬁt in DSRCT and had more toxicity with
intraperitoneal cisplatin and doxorubicin, no further mul-
tiagent chemotherapy was used in the postoperative period.
Our patient was discharged from the hospital on post-op day
7 and subsequently began cycles of adjuvant temozolomide
+ irinotecan, a non-cross-resistant regimen.
The combination of CHPP and radiotherapy would be
expected to result in scarring and adhesions and limit ability
to do second-look surgery. Thus the local control option for
isolated recurrent perihepatic lesions was radio frequency
ablation and cryoablation (Figure 5). The use of this tech-
nique in pediatric patients with metastatic DSRCT has been
previously reported [30]. Heating increases the expression
of heat shock proteins in hepatocellular carcinoma; these
molecularchaperonesareimportantforantigenpresentation
[31]. Cryoablation is a technique to not only kill tumor cells,
but avoid protein denaturation by RFA. This approach using
heat (RFA probe), then cryoablation can be considered an
“in vivo vaccine” and was ﬁrst developed by S Markovic at
Mayo Clinic; a clinical trial is currently underway to study
eﬀectiveness in melanoma hepatic metastases.
We found that PET-CT imaging was useful for the eval-
uation of the extension of disease at presentation as well as a
usefultool for monitoring the response to therapy; therefore,
weperformedPET-CTscansinourpatientatevery3months
interval. The use of PET for DSRCT has been described
previously by Rosoﬀ and Bayliﬀ [16]. This is the ﬁrst report
of its use in children after the use of continuous peritoneal
perfusion and to monitor for recurrence. Reaching a no ev-
idence of disease (NED) status and excellent quality of life
was possible in our patient with very extensive abdom-
inopelvic DSRCT using outpatient therapy. Principles and
techniques should be applicable to other high-risk young
patients with DSRCT.
Finally, because inherent and seemingly inevitable
chemotherapy resistance of DSRCT, in addition to eﬀorts
at best local control, novel therapeutic ideas are needed in
the event of a relapse. The options include new agents such
as small molecule inhibitor of C-kit and PDGFR, imatinib
mesylate which has a remarkable safety proﬁle. The current
experienceoftheuseofimatinibinDSRCThasbeenrecently
reportedbyBondetal.,wherenoobjectiveresponsewasseen
atthedoseandscheduletested[32].Othermoleculesinclude
IGF-R1 antibodies thatinhibit downstream signaling ofboth
the mTOR and MAP kinase pathways that are important in
both proliferation and resistance to apoptosis of a variety of
cancers. It is noteworthy that patients with Ewing’s family
of tumors responded in phase I trial of R1507. The SARC
consortium phase II trial of R1507 opened in early 2008
(SARC 011; sarctrials.com) and should provide a determine
whether this agent is active in DSRCT in ages 12 and up
[33]. The safety proﬁle of a multiple ascending dose study
for R1507 for children ages 2 to 17 with advanced solid8 Sarcoma
tumors (http://www.clinicaltrials.gov/)i se x p e c t e dt oa l l o w
participation of younger cohorts (ages 2 and up) on SARC
011 in 2008.
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